Skip to main content
Premium Trial:

Request an Annual Quote

Cellumen Spins Off Personalized Medicine Company

NEW YORK (GenomeWeb News) – Cellumen said yesterday that it has spun off its personalized medicine unit, called Cernostics Pathology.
 
Pittsburgh-based Cellumen said that Cernostics will provide digital imaging pathology and tissue-based diagnostics products and services for personalized medicine applications. It added that the spinout would build on Cellumen’s current collaborations with partners, such as the Mayo Clinic and Foundation, in developing a breast cancer diagnostic and theranostic test.
 
“Cellumen will maintain its core business by focusing on the interface between early drug discovery and early toxicity testing,” Lansing Taylor, CEO of Cellumen, said in a statement.
 
Taylor will serve as chairman of Cernostics Pathology, and Michel Nederlof will join the new firm as president and chief technology officer. Nederlof recently was the founder and president of QED Imaging, which is now part of Media Cybernetics.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more